Subsequent malignancies after allogeneic hematopoietic stem cell transplantation
We evaluated 979 patients for the development of post‐transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo‐HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD,...
Gespeichert in:
| Veröffentlicht in: | Clinical transplantation 2017-07, Vol.31 (7), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 7 |
| container_start_page | |
| container_title | Clinical transplantation |
| container_volume | 31 |
| creator | Gündüz, Mehmet Özen, Mehmet Şahin, Uğur Toprak, Selami Koçak Civriz Bozdağ, Sinem Kurt Yüksel, Meltem Arslan, Önder Özcan, Muhit Demirer, Taner Beksaç, Meral İlhan, Osman Gürman, Günhan Topçuoğlu, Pervin |
| description | We evaluated 979 patients for the development of post‐transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo‐HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo‐HSCT to the development of PTLD was 9 (3‐20) months and that from allo‐HSCT to the development of solid tumors was 93 (6‐316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The cumulative incidence of developing subsequent malignancy in patients with benign hematological diseases as the transplant indication was 7.4%±4.2 SE at 5 years. More subsequent malignancy developed in patients having ≥1 year chronic graft‐vs‐host disease (GVHD; 3.7% in ≥1 year chronic GVHD and 0.7% in |
| doi_str_mv | 10.1111/ctr.12987 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891144497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1891144497</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3257-b930e0cd16919516cfe5523529d2583ad6f926a95db64887c6667cac738a71783</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AdQlrBI60fs2EtU8ZKQQFDWkeNMSlDiFNsR6t_jksKO2cxDR0eji9A5wXMSa2GCmxOqZH6ApoQplWJM6CGaYoVpnAWboBPvP-JVEMGP0YTKjFGJ6RQ9vw6lh88BbEg63TZrq61pwCe6DuAS3bb9Giw0JnmHTod-0zcQ4uYDdImBtk2C09ZvWm2DDk1vT9FRrVsPZ_s-Q2-3N6vlffr4dPewvH5MDaM8T0vFMGBTEaGI4kSYGjinjFNVUS6ZrkStqNCKV6XIpMyNECI32uRM6pzkks3Q5ejduD6-70PRNX73kLbQD74gUhGSZZnKI3o1osb13juoi41rOu22BcHFLsAiBlj8BBjZi712KDuo_sjfxCKwGIGvpoXt_6ZiuXoZld9SHHqP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1891144497</pqid></control><display><type>article</type><title>Subsequent malignancies after allogeneic hematopoietic stem cell transplantation</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Gündüz, Mehmet ; Özen, Mehmet ; Şahin, Uğur ; Toprak, Selami Koçak ; Civriz Bozdağ, Sinem ; Kurt Yüksel, Meltem ; Arslan, Önder ; Özcan, Muhit ; Demirer, Taner ; Beksaç, Meral ; İlhan, Osman ; Gürman, Günhan ; Topçuoğlu, Pervin</creator><creatorcontrib>Gündüz, Mehmet ; Özen, Mehmet ; Şahin, Uğur ; Toprak, Selami Koçak ; Civriz Bozdağ, Sinem ; Kurt Yüksel, Meltem ; Arslan, Önder ; Özcan, Muhit ; Demirer, Taner ; Beksaç, Meral ; İlhan, Osman ; Gürman, Günhan ; Topçuoğlu, Pervin</creatorcontrib><description>We evaluated 979 patients for the development of post‐transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo‐HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo‐HSCT to the development of PTLD was 9 (3‐20) months and that from allo‐HSCT to the development of solid tumors was 93 (6‐316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The cumulative incidence of developing subsequent malignancy in patients with benign hematological diseases as the transplant indication was 7.4%±4.2 SE at 5 years. More subsequent malignancy developed in patients having ≥1 year chronic graft‐vs‐host disease (GVHD; 3.7% in ≥1 year chronic GVHD and 0.7% in <1 year chronic GVHD patient groups, P=.002). Subsequent epithelial tumor risk was higher in ≥1 year chronic GVHD patients than <1 year (3.7% vs 0.1%, P<.001). In multivariate analysis, benign hematological diseases as transplant indication (RR: 5.6, CI 95%: 1.4‐22.3, P=.015) and ≥1 year chronic GVHD (RR: 7.1, 95% CI: 2.3‐22.5, P=.001) were associated with the development of subsequent malignancy.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/ctr.12987</identifier><identifier>PMID: 28432802</identifier><language>eng</language><publisher>Denmark</publisher><subject>Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; chronic GVHD ; epithelial tumor ; Female ; Follow-Up Studies ; Graft vs Host Disease - etiology ; Graft vs Host Disease - pathology ; Hematologic Neoplasms - complications ; Hematologic Neoplasms - therapy ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local - etiology ; Neoplasm Recurrence, Local - pathology ; Neoplasms, Second Primary - etiology ; Neoplasms, Second Primary - pathology ; Prognosis ; PTLD ; Risk Factors ; subsequent malignancy ; transplantation ; Young Adult</subject><ispartof>Clinical transplantation, 2017-07, Vol.31 (7), p.n/a</ispartof><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3257-b930e0cd16919516cfe5523529d2583ad6f926a95db64887c6667cac738a71783</citedby><cites>FETCH-LOGICAL-c3257-b930e0cd16919516cfe5523529d2583ad6f926a95db64887c6667cac738a71783</cites><orcidid>0000-0002-0910-9307 ; 0000-0003-4407-5461</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fctr.12987$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fctr.12987$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28432802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gündüz, Mehmet</creatorcontrib><creatorcontrib>Özen, Mehmet</creatorcontrib><creatorcontrib>Şahin, Uğur</creatorcontrib><creatorcontrib>Toprak, Selami Koçak</creatorcontrib><creatorcontrib>Civriz Bozdağ, Sinem</creatorcontrib><creatorcontrib>Kurt Yüksel, Meltem</creatorcontrib><creatorcontrib>Arslan, Önder</creatorcontrib><creatorcontrib>Özcan, Muhit</creatorcontrib><creatorcontrib>Demirer, Taner</creatorcontrib><creatorcontrib>Beksaç, Meral</creatorcontrib><creatorcontrib>İlhan, Osman</creatorcontrib><creatorcontrib>Gürman, Günhan</creatorcontrib><creatorcontrib>Topçuoğlu, Pervin</creatorcontrib><title>Subsequent malignancies after allogeneic hematopoietic stem cell transplantation</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>We evaluated 979 patients for the development of post‐transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo‐HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo‐HSCT to the development of PTLD was 9 (3‐20) months and that from allo‐HSCT to the development of solid tumors was 93 (6‐316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The cumulative incidence of developing subsequent malignancy in patients with benign hematological diseases as the transplant indication was 7.4%±4.2 SE at 5 years. More subsequent malignancy developed in patients having ≥1 year chronic graft‐vs‐host disease (GVHD; 3.7% in ≥1 year chronic GVHD and 0.7% in <1 year chronic GVHD patient groups, P=.002). Subsequent epithelial tumor risk was higher in ≥1 year chronic GVHD patients than <1 year (3.7% vs 0.1%, P<.001). In multivariate analysis, benign hematological diseases as transplant indication (RR: 5.6, CI 95%: 1.4‐22.3, P=.015) and ≥1 year chronic GVHD (RR: 7.1, 95% CI: 2.3‐22.5, P=.001) were associated with the development of subsequent malignancy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>chronic GVHD</subject><subject>epithelial tumor</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - pathology</subject><subject>Hematologic Neoplasms - complications</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - etiology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasms, Second Primary - etiology</subject><subject>Neoplasms, Second Primary - pathology</subject><subject>Prognosis</subject><subject>PTLD</subject><subject>Risk Factors</subject><subject>subsequent malignancy</subject><subject>transplantation</subject><subject>Young Adult</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWw4AdQlrBI60fs2EtU8ZKQQFDWkeNMSlDiFNsR6t_jksKO2cxDR0eji9A5wXMSa2GCmxOqZH6ApoQplWJM6CGaYoVpnAWboBPvP-JVEMGP0YTKjFGJ6RQ9vw6lh88BbEg63TZrq61pwCe6DuAS3bb9Giw0JnmHTod-0zcQ4uYDdImBtk2C09ZvWm2DDk1vT9FRrVsPZ_s-Q2-3N6vlffr4dPewvH5MDaM8T0vFMGBTEaGI4kSYGjinjFNVUS6ZrkStqNCKV6XIpMyNECI32uRM6pzkks3Q5ejduD6-70PRNX73kLbQD74gUhGSZZnKI3o1osb13juoi41rOu22BcHFLsAiBlj8BBjZi712KDuo_sjfxCKwGIGvpoXt_6ZiuXoZld9SHHqP</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Gündüz, Mehmet</creator><creator>Özen, Mehmet</creator><creator>Şahin, Uğur</creator><creator>Toprak, Selami Koçak</creator><creator>Civriz Bozdağ, Sinem</creator><creator>Kurt Yüksel, Meltem</creator><creator>Arslan, Önder</creator><creator>Özcan, Muhit</creator><creator>Demirer, Taner</creator><creator>Beksaç, Meral</creator><creator>İlhan, Osman</creator><creator>Gürman, Günhan</creator><creator>Topçuoğlu, Pervin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0910-9307</orcidid><orcidid>https://orcid.org/0000-0003-4407-5461</orcidid></search><sort><creationdate>201707</creationdate><title>Subsequent malignancies after allogeneic hematopoietic stem cell transplantation</title><author>Gündüz, Mehmet ; Özen, Mehmet ; Şahin, Uğur ; Toprak, Selami Koçak ; Civriz Bozdağ, Sinem ; Kurt Yüksel, Meltem ; Arslan, Önder ; Özcan, Muhit ; Demirer, Taner ; Beksaç, Meral ; İlhan, Osman ; Gürman, Günhan ; Topçuoğlu, Pervin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3257-b930e0cd16919516cfe5523529d2583ad6f926a95db64887c6667cac738a71783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>chronic GVHD</topic><topic>epithelial tumor</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - pathology</topic><topic>Hematologic Neoplasms - complications</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - etiology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasms, Second Primary - etiology</topic><topic>Neoplasms, Second Primary - pathology</topic><topic>Prognosis</topic><topic>PTLD</topic><topic>Risk Factors</topic><topic>subsequent malignancy</topic><topic>transplantation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gündüz, Mehmet</creatorcontrib><creatorcontrib>Özen, Mehmet</creatorcontrib><creatorcontrib>Şahin, Uğur</creatorcontrib><creatorcontrib>Toprak, Selami Koçak</creatorcontrib><creatorcontrib>Civriz Bozdağ, Sinem</creatorcontrib><creatorcontrib>Kurt Yüksel, Meltem</creatorcontrib><creatorcontrib>Arslan, Önder</creatorcontrib><creatorcontrib>Özcan, Muhit</creatorcontrib><creatorcontrib>Demirer, Taner</creatorcontrib><creatorcontrib>Beksaç, Meral</creatorcontrib><creatorcontrib>İlhan, Osman</creatorcontrib><creatorcontrib>Gürman, Günhan</creatorcontrib><creatorcontrib>Topçuoğlu, Pervin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gündüz, Mehmet</au><au>Özen, Mehmet</au><au>Şahin, Uğur</au><au>Toprak, Selami Koçak</au><au>Civriz Bozdağ, Sinem</au><au>Kurt Yüksel, Meltem</au><au>Arslan, Önder</au><au>Özcan, Muhit</au><au>Demirer, Taner</au><au>Beksaç, Meral</au><au>İlhan, Osman</au><au>Gürman, Günhan</au><au>Topçuoğlu, Pervin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subsequent malignancies after allogeneic hematopoietic stem cell transplantation</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2017-07</date><risdate>2017</risdate><volume>31</volume><issue>7</issue><epage>n/a</epage><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>We evaluated 979 patients for the development of post‐transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo‐HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo‐HSCT to the development of PTLD was 9 (3‐20) months and that from allo‐HSCT to the development of solid tumors was 93 (6‐316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The cumulative incidence of developing subsequent malignancy in patients with benign hematological diseases as the transplant indication was 7.4%±4.2 SE at 5 years. More subsequent malignancy developed in patients having ≥1 year chronic graft‐vs‐host disease (GVHD; 3.7% in ≥1 year chronic GVHD and 0.7% in <1 year chronic GVHD patient groups, P=.002). Subsequent epithelial tumor risk was higher in ≥1 year chronic GVHD patients than <1 year (3.7% vs 0.1%, P<.001). In multivariate analysis, benign hematological diseases as transplant indication (RR: 5.6, CI 95%: 1.4‐22.3, P=.015) and ≥1 year chronic GVHD (RR: 7.1, 95% CI: 2.3‐22.5, P=.001) were associated with the development of subsequent malignancy.</abstract><cop>Denmark</cop><pmid>28432802</pmid><doi>10.1111/ctr.12987</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0910-9307</orcidid><orcidid>https://orcid.org/0000-0003-4407-5461</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-0063 |
| ispartof | Clinical transplantation, 2017-07, Vol.31 (7), p.n/a |
| issn | 0902-0063 1399-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891144497 |
| source | MEDLINE; Wiley Online Library |
| subjects | Adolescent Adult Aged Child Child, Preschool chronic GVHD epithelial tumor Female Follow-Up Studies Graft vs Host Disease - etiology Graft vs Host Disease - pathology Hematologic Neoplasms - complications Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - adverse effects Humans Male Middle Aged Neoplasm Recurrence, Local - etiology Neoplasm Recurrence, Local - pathology Neoplasms, Second Primary - etiology Neoplasms, Second Primary - pathology Prognosis PTLD Risk Factors subsequent malignancy transplantation Young Adult |
| title | Subsequent malignancies after allogeneic hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T07%3A46%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subsequent%20malignancies%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=Clinical%20transplantation&rft.au=G%C3%BCnd%C3%BCz,%20Mehmet&rft.date=2017-07&rft.volume=31&rft.issue=7&rft.epage=n/a&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/ctr.12987&rft_dat=%3Cproquest_cross%3E1891144497%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1891144497&rft_id=info:pmid/28432802&rfr_iscdi=true |